Search results
Results from the WOW.Com Content Network
Study 3014 was a key clinical trial of approximately 24,000 patients which Sanofi-Aventis submitted to the FDA to seek approval for Ketek. The doctor who treated the most patients in Study 3014 (about 400), Maria "Anne" Kirkman Campbell, served a 57-month sentence in federal prison after pleading guilty to mail fraud, by defrauding Aventis and ...
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
2004: merger of Aventis with and into Sanofi. The new Sanofi-Aventis Group becomes the world's 3rd largest pharmaceutical company, behind Pfizer and GlaxoSmithKline. Aventis Pasteur, the vaccine division of the Sanofi-Aventis Group, changes its name to Sanofi Pasteur. 2008: Sanofi Pasteur acquires Acambis plc, a biotech company.
Rhône-Poulenc (French pronunciation: [ʁon pulɛ̃k]) was a French chemical and pharmaceutical company founded in 1928.In 1999, it merged with Hoechst AG to form Aventis.As of 2015, the pharmaceutical operations of Rhône-Poulenc are part of Sanofi and the chemicals divisions are part of Solvay group and Bayer Crop Science.
Roussel Uclaf S.A. was a French pharmaceutical company and one of several predecessor companies of today's Sanofi. It was the second largest French pharmaceutical company [6] before it was acquired by Hoechst AG of Frankfurt, Germany in 1997, with pharmaceutical operations combined into the Hoechst Marion Roussel (HMR) division in the United States.
Hoechst AG (German pronunciation: [ˈhøːçst]) was a German chemicals, later life sciences, company that became Aventis Deutschland after its merger with France's Rhône-Poulenc S.A. in 1999. With the new company's 2004 merger with Sanofi-Synthélabo , it became a subsidiary of the resulting Sanofi-Aventis pharmaceuticals group.
Sanofi-Aventis's second announcement today also shows a strategy shift. The drugmaker says it will invest 150 million euros ($201.4 million) ...
On March 9, 2010, Sanofi-Aventis announced [6] it had exercised an option to combine Merial with Intervet/Schering Plough, the animal health business of Merck. The new joint venture would be equally owned by Merck and Sanofi-Aventis. On March 22, 2011, they announced the mutual termination of their agreement to form a new animal health joint ...